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Reply to the Editor:
Drs Ascione and Angelini have written to
emphasize the contributions they have pre-
viously made in conducting and reporting
randomized clinical trials of off-pump cor-
onary artery bypass grafting (CABG) ver-
sus CABG with cardiopulmonary bypass
(CPB). Indeed, these authors and their co-
workers have made numerous contribu-
tions to our understanding of patient out-
comes with these two surgical techniques.
Among their contributions is a series of
publications reporting various outcome
variables from two groups of selected pa-
tients randomized to undergo OPCAB or
conventional CABG/CPB. As they have
noted in their own letter to the Editor, the
first of these groups of patients was se-
lected to exclude those requiring grafts to
the distal branches of the left circumflex
artery, whereas the second group was se-
lected to exclude patients with previous
stroke and renal failure, as these were con-
sidered potentially confounding variables.
Both studies reported important advantages
of OPCAB over conventional CABG/CPB
and were landmark publications. Neither
rigorously documented the completeness of
revascularization. Indeed, BHACAS 2 re-
ported that 70% of CPB patients versus
56% of OPCAB patients had 3 grafts or
more; this difference (the manuscript does
not state whether this was a statistically
significant difference) was especially noted
in grafts to the lateral wall of the left ven-
tricle. The mean number of grafts per pa-
tient in each group was not reported.1
In the SMART trial,2 my coauthors (to
each of whom I am grateful) and I sought
to demonstrate that OPCAB could be
safely applied to the general population of
patients referred for elective surgical coro-
nary revascularization and that an equiva-
lently optimal revascularization could be
achieved in both groups. Patients were not
excluded on the basis of any coronary anat-
omy, ventricular dysfunction, or comor-
bidities, including prior stroke or renal fail-
ure. Indeed we believed it important to
randomize “all comers,” and we did so.
Thus, this trial compared outcomes among
truly unselected patients referred for non-
emergency CABG. (Among the numerous
demographic variables tracked, incidence
of prior stroke was regrettably different
between the randomized groups. This is a
simple function of sample size.) We be-
lieved it important to document the optimal
revascularization that should be performed
for each patient before randomization. The
grafts actually performed were then com-
pared with those intended, creating a for-
mal index of completeness of revascular-
ization (ICOR), which was found to be
virtually identical between groups. The
ICOR was also similar between groups for
the lateral wall of the left ventricle, docu-
menting that OPCAB with modern stabi-
lizing devices could provide complete re-
vascularization of all areas of the heart in
unselected patients. Other end points, in-
cluding serum levels of myocardial en-
zymes, transfusion requirement, and length
of stay, strongly favored the OPCAB
group, consistent with the findings of pre-
vious randomized trials in selected pa-
tients.
We look forward to reporting angio-
graphic graft patency and longer term out-
comes from these randomized cohorts as
those data become available, building on
the important foundation that Drs Ascione,
Angelini,1 Van Dijk,3 Diegeler,4 Czerny,5
Zamvar,6 and others have laid.
“I prefer nothing more than that I
should be true to myself and they to
themselves.”
—Julius Caesar, letter
to Cicero, quoted in Cicero, Letters
to Atticus, 9.16.2.
John D. Puskas, MD
Associate Professor of Surgery
(Cardiothoracic)
Emory University
Crawford Long Hospital
Atlanta, GA 30308
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Abdominal tumors with cavoatrial
extension
To the Editor:
We congratulate Chiappini and associates1
on their outstanding results in the treatment
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of cavoatrial tumors with hypothermic cir-
culatory arrest. We previously reported on
a similar series of 12 patients operated on
between 1990 and 1995,2 and we take this
opportunity to outline several aspects not
described in the previously published re-
view.
Two of our patients died (multiorgan
failure). Both showed a preoperative ejec-
tion fraction less than 30% and no cardiac
condition amenable to surgical correction.
Left ventricular dysfunction may therefore
represent a relative contraindication for op-
eration (at least, for prolonged circulatory
support and deep hypothermic techniques).
We had a substantially higher rate of post-
operative complications. A serum creati-
nine level rise of more than 2 mg/dL was
observed in 5 of 12 cases, although this
condition was present before the operation
in 3 of the 5, and dialysis was never re-
quired. Transient jaundice occurred in 9 of
12 patients. It can be speculated that tumor
thrombus may impair hepatic venous drain-
age, and thus hepatic “functional reserve,”
despite normal results of preoperative liver
function tests.
From a technical standpoint, we agree
that hypothermic circulatory arrest is the
optimal approach. We performed an atri-
otomy before cavotomy in all cases to
gain open distal access and reduce em-
bolic risks. This preceded en bloc tumor
resection through the inferior vena cava
(IVC). If the thrombus is unusually ad-
herent to the IVC, infiltration should be
suspected and a more aggressive resec-
tion considered; in our experience, 1 such
patient died of local tumor recurrence. In
addition, if circulatory support is not
used, specific maneuvers may be hazard-
ous; clamping of the porta hepatis can
produce acute spleen rupture in patients
without chronic portal hypertension.3
Chiappini and associates1 used the chev-
ron incision, whereas we preferred a me-
dian sternolaparotomy in all cases. The
former is optimal to expose right-sided
lesions, which are much more common
because of the IVC location and shorter
length of the renal vein. However, we
encountered left-sided tumors with IVC
extension in 25% of our patients.
Finally, all late deaths in our series were
related to metastatic cancer. Chiappini and
associates1 reported that 4 of 13 patients
had distant metastases identified before the
operation. Although obstructive symptoms
may be successfully palliated, we believe
that an operation is contraindicated in such
cases. This does not apply to patients who
require associated pulmonary tumor embo-
lectomy.
Marco Pocar, MD, PhD
Francesco Donatelli, MD
Cattedra di Cardiochirurgia
Universita` degli Studi di Milano
Milan, Italy
References
1. Chiappini B, Savini C, Marinelli G, Suarez
SM, Di Eusanio M, Fiorani V, et al.
Cavoatrial tumor thrombus: single-stage sur-
gical approach with profound hypothermia
and circulatory arrest, including a review of
the literature. J Thorac Cardiovasc Surg.
2002;14:684-8.
2. Donatelli F, Pocar M, Triggiani M, Moneta
A, Lazzarini I, D’Ancona G, et al. Surgery of
cavo-atrial renal carcinoma employing circu-
latory arrest: immediate and mid-term results.
Cardiovasc Surg. 1998;6:166-70.
3. Baniel J, Bihrle R, Wahle GR, Foster RS.
Splenic rupture during occlusion of the porta
hepatis in resection of tumors with caval ex-
tension. J Urol. 1994;151:992-4.
doi:10.1016/S0022-5223(03)01219-4
Reply to the Editor:
My colleagues and I thank Pocar and Do-
natelli for their appreciation of our article.
None of our patients showed a low preop-
erative ejection fraction like that seen in 2
patients in their study, and we agree that
left ventricular dysfunction may represent a
relative contraindication for operation with
prolonged circulatory support and deep hy-
pothermic techniques. Early postoperative
outcomes in our study population confirm
that cardiopulmonary bypass with deep hy-
pothermic circulatory arrest carries reduced
risks of warm renal and hepatic ischemia.
As do Pocar and Donatelli, we prefer to
perform atriotomy before cavotomy to gain
open distal access and reduce embolic
risks. In our experience the chevron inci-
sion is the best surgical approach, provid-
ing the safest and widest exposure for re-
moving these tumors and tumor thrombus.
We agree with Pocar and Donatelli re-
garding the contraindication of surgery for
patients with diffuse metastatic cancer be-
cause of the high risk/benefit ratio.
Bruno Chiappini, MD
Department of Cardiovascular Surgery
Policlinico S. Orsola-Malpighi
University of Bologna
Bologna, Italy
doi:10.1016/S0022-5223(03)01220-0
Partial left ventriculectomy in
patients with neoplasms and severe
heart failure who are not candidates
for cardiac transplantation
To the Editor:
I read the article of Casarotto and col-
leagues1 with great interest. The article de-
scribed a patient with Castleman disease
who was treated with chemotherapy, lead-
ing to a dilated cardiomyopathy. Because
of the neoplasm, cardiac transplantation
was contraindicated. Because of a progre-
dient severe heart failure, the patient had to
be supported with a Novacor (World Heart
Corporation, Ottawa, Ontario, Canada) left
ventricular assist device (LVAD). After a
total of 1512 days, the patient had no signs
of a relapse of Castleman disease and un-
derwent orthotopic heart transplantation.
The number of patients with severe
heart failure after chemotherapy for neo-
plasms should not be underestimated: from
1990 to 1996, cardiac transplantation was
performed in 89 selected patients in the
United States for this indication.2 The num-
ber of patients in whom cardiac transplanta-
tion cannot be performed because there is no
proof of cure of the neoplasm is probably
much higher. Therefore these patients are not
so rare as might be supposed, and alternative
treatment concepts are necessary.
Recently, I introduced a canine model
for research on partial left ventriculectomy
(PLV).3,4 Heart failure was induced by in-
tracoronary doxorubicin administration,
leading to a dilated cardiomyopathy with
histologic myocardial changes similar to
those described by Casarotto and col-
leagues.1 PLV was performed by resecting
the interpapillary segment of the left ven-
tricle (group 2). Measurement of hemody-
namic and echocardiographic parameters
demonstrated an improvement of left ven-
tricular function relative to a control group
without PLV (group 1; Table 1).
PLV thus may also work in chemother-
apy-induced heart failure, and I propose it
as an alternative treatment option. PLV has
some advantages relative to LVAD implan-
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